Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of (18)F-BF3-Cy3-ACUPA and (68)Ga-PSMA PET/MRI Journal Article

   


Authors: Aras, O.; Demirdag, C.; Kommidi, H.; Ting, R.; Sayman, H. B.
Article Title: Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of (18)F-BF3-Cy3-ACUPA and (68)Ga-PSMA PET/MRI
Abstract: Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.
Keywords: colorectal cancer; psma; pet/mri; 68ga-psma; 18f-bf3-cy3-acupa
Journal Title: Nuclear Medicine Review
Volume: 25
Issue: 2
ISSN: 1506-9680
Publisher: Via Medica  
Date Published: 2022-08-05
Start Page: 129
End Page: 130
Language: English
DOI: 10.5603/NMR.a2022.0027
PUBMED: 35699591
PROVIDER: scopus
PMCID: PMC9878462
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136061423&doi=10.5603%2fNMR.a2022.0027&partnerID=40&md5=1c8f047a5e5a0976d992d39b8016c285
Notes: Article -- Export Date: 1 September 2022 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Omer Aras
    75 Aras
Related MSK Work